Pain Prevalence During Cancer Treatment: A Systematic Review and Meta-Analysis

Evenepoel, Margaux; Haenen, Vincent; Baerdemaecker, Tom De; Devoogdt, Nele; Dams, Lore; Dijck, Sophie Van; Gucht, Elien Van der; Groef, An De

doi:10.1016/j.jpainsymman.2021.09.011

Cited by 48 publications

(28 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The search string was inspired by the search strings of van den Beuken-van Everdingen et al (2016), Evenepoel et al (2022) and Rietjens et al (2019) [7,9,29]. Important search terms were "pain", "symptom", "prevalence", and "cancer".…”

Section: Search Strategymentioning

confidence: 99%

“…Despite increased attention to the assessment and management of pain in cancer patients, previous research concluded that no major advances have been made in the management of cancer pain in 50 years [7,8]. A recent systematic literature review on the prevalence of pain during cancer treatment by Evenepoel et al (2022) showed that pain during cancer treatment remains high during and up to three months after curative cancer treatment [9].…”

Section: Introductionmentioning

confidence: 99%

“…Many new studies have been published on the prevalence of cancer pain since the 2016 systematic literature review of van den Beuken-van Everdingen et al The review of Evenepoel et al (2022) was limited to cancer patients receiving curative treatment, excluding other phases of the disease. Therefore, the aim of this systematic literature review was to assess the prevalence of cancer pain and pain severity in cancer patients throughout all phases of the disease.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis

Snijders

Brom

Theunissen

et al. 2023

Cancers

View full text Add to dashboard Cite

Experiencing pain and insufficient relief can be devastating and negatively affect a patient’s quality of life. Developments in oncology such as new treatments and adjusted pain management guidelines may have influenced the prevalence of cancer pain and severity in patients. This review aims to provide an overview of the prevalence and severity of pain in cancer patients in the 2014–2021 literature period. A systematic literature search was performed using the databases PubMed, Embase, CINAHL, and Cochrane. Titles and abstracts were screened, and full texts were evaluated and assessed on methodological quality. A meta-analysis was performed on the pooled prevalence and severity rates. A meta-regression analysis was used to explore differences between treatment groups. We identified 10,637 studies, of which 444 studies were included. The overall prevalence of pain was 44.5%. Moderate to severe pain was experienced by 30.6% of the patients, a lower proportion compared to previous research. Pain experienced by cancer survivors was significantly lower compared to most treatment groups. Our results imply that both the prevalence of pain and pain severity declined in the past decade. Increased attention to the assessment and management of pain might have fostered the decline in the prevalence and severity of pain.

show abstract

Section: Search Strategymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis

Snijders

Brom

Theunissen

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Cancer and anticancer therapies can often lead to physical and psychological burdens in patients. One of the serious burdens is cancer-related pain, affecting approximately 40% of patients with cancer [ 159 ]. Patients can experience pain in every stage of cancer until the end of life.…”

Section: Roles Of Hif-1 In Anticancer Drug Resistance and Cancer-rela...mentioning

confidence: 99%

Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain

Bui

Nguyen

Lee

et al. 2022

Cancers

View full text Add to dashboard Cite

Hypoxia-inducible factor-1 (HIF-1) is a key transcription factor that regulates the transcription of many genes that are responsible for the adaptation and survival of tumor cells in hypoxic environments. Over the past few decades, tremendous efforts have been made to comprehensively understand the role of HIF-1 in tumor progression. Based on the pivotal roles of HIF-1 in tumor biology, many HIF-1 inhibitors interrupting expression, stabilization, DNA binding properties, or transcriptional activity have been identified as potential therapeutic agents for various cancers, yet none of these inhibitors have yet been successfully translated into clinically available cancer treatments. In this review, we briefly introduce the regulation of the HIF-1 pathway and summarize its roles in tumor cell proliferation, angiogenesis, and metastasis. In addition, we explore the implications of HIF-1 in the development of drug resistance and cancer-related pain: the most commonly encountered obstacles during conventional anticancer therapies. Finally, the current status of HIF-1 inhibitors in clinical trials and their perspectives are highlighted, along with their modes of action. This review provides new insights into novel anticancer drug development targeting HIF-1. HIF-1 inhibitors may be promising combinational therapeutic interventions to improve the efficacy of current cancer treatments and reduce drug resistance and cancer-related pain.

show abstract

“…1 The biopsychosocial contributors to pain post-breast cancer treatment (adapted from Explain Pain Supercharged [46]). The experience of pain is determined not only by the stimulation of tissues such as muscles or nerves (biological level), but also by how a person is feeling and thinking about the pain (psychological level) as well as one's personal environment and how one feels supported within it (social level) [35] In the early stage of cancer treatment, acute pain caused by surgery, radiotherapy and/or chemotherapy is present in many cases [47]. After surgery and radiotherapy in particular, (painful) dysfunctions related to the musculoskeletal system are often described [48].…”

Section: Biopsychosocial Contributors To Pain Post-breast Cancer Trea...mentioning

confidence: 99%

Treating persistent pain after breast cancer: practice gaps and future directions

et al. 2022

Self Cite

View full text Add to dashboard Cite

This paper discusses the growing problem of persisting pain after successful treatment of breast cancer and presents recommendations for improving pain-related outcomes for this group. We discuss the dominant treatment approach for persisting pain post-breast cancer treatment and draw contrasts with contemporary treatment approaches to persistent pain in noncancer-related populations. We discuss modern application of the biopsychosocial model of pain and the notion of variable sensitivity within the pain system, moment by moment and over time. We present the implications of increasing sensitivity over time for treatment selection and implementation. By drawing on transformative changes in treatment approaches to persistent non-cancer-related pain, we describe the potentially powerful role that an intervention called pain science education, which is now recommended in clinical guidelines for musculoskeletal pain, may play in improving pain and disability outcomes after successful breast cancer treatment. Finally, we present several research recommendations that centre around adaptation of the content and delivery models of contemporary pain science education, to the post-breast cancer context.

show abstract

Pain Prevalence During Cancer Treatment: A Systematic Review and Meta-Analysis

Cited by 48 publications

References 61 publications

Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis

Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis

Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain

Treating persistent pain after breast cancer: practice gaps and future directions

Contact Info

Product

Resources

About